In addition, immunohistochemistry of tumor tissue showed higher expression of ITGB8, TGF-β1, and TGF-β1 LAP, which indicates latent TGF-β1 activation in recurrent cancer tissues compared with non-recurrent cancer tissues after BCG treatment. This evidence concerns the gene ITGB8 and neoplasm.